Published in Mol Cancer Ther on May 22, 2013
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol (2014) 2.23
Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res (2014) 2.10
Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res (2015) 1.70
Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget (2014) 1.51
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer (2014) 1.45
Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. Cancer Res (2015) 1.24
Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene (2014) 1.15
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer (2014) 1.14
Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer (2014) 1.11
Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes. Prostate (2014) 1.07
Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Res (2014) 1.05
Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. Am J Clin Exp Urol (2015) 1.05
Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Oncogene (2014) 0.97
Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol (2015) 0.94
Wnt signaling in castration-resistant prostate cancer: implications for therapy. Am J Clin Exp Urol (2014) 0.93
The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers (Basel) (2014) 0.91
NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer. Mol Cancer Ther (2015) 0.88
Splicing variants of androgen receptor in prostate cancer. Am J Clin Exp Urol (2013) 0.88
Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. Endocr Relat Cancer (2014) 0.86
Targeting molecular resistance in castration-resistant prostate cancer. BMC Med (2015) 0.84
Constitutive activity of the androgen receptor. Adv Pharmacol (2014) 0.84
Persistent androgen receptor addiction in castration-resistant prostate cancer. J Hematol Oncol (2015) 0.84
Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget (2016) 0.83
Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis (2016) 0.83
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. Clin Med Insights Oncol (2016) 0.83
Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Rev Anticancer Ther (2014) 0.82
Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance. Front Pharmacol (2015) 0.82
NF-κB and androgen receptor variant expression correlate with human BPH progression. Prostate (2015) 0.81
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. Int J Biol Sci (2016) 0.81
Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation. Prostate (2015) 0.81
TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. Cancer Sci (2015) 0.80
Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression. Prostate (2014) 0.79
Dendritic cell maturation and survival are differentially regulated by TNFR1 and TNFR2. J Immunol (2014) 0.79
Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells. Oncotarget (2015) 0.78
20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer. PLoS One (2014) 0.77
An imaging agent to detect androgen receptor and its active splice variants in prostate cancer. JCI Insight (2016) 0.77
Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother (2015) 0.77
Role of BioResponse 3,3'-Diindolylmethane in the Treatment of Human Prostate Cancer: Clinical Experience. Med Princ Pract (2015) 0.77
Overview on the complexity of androgen receptor-targeted therapy for prostate cancer. Cancer Cell Int (2015) 0.77
COP9 subunits 4 and 5 target soluble guanylyl cyclase α1 and p53 in prostate cancer cells. Mol Endocrinol (2014) 0.76
The Androgen Receptor Regulates PPARγ Expression and Activity in Human Prostate Cancer Cells. J Cell Physiol (2016) 0.75
Emerging data on androgen receptor splice variants in prostate cancer. Endocr Relat Cancer (2016) 0.75
Role of androgen receptor splice variants in prostate cancer metastasis. Asian J Urol (2016) 0.75
Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. Oncotarget (2016) 0.75
Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated AR(ser81). Genes Cancer (2015) 0.75
Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer. Expert Opin Ther Targets (2016) 0.75
Marine-derive chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration. Acta Pharmacol Sin (2017) 0.75
Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression. Oncotarget (2016) 0.75
NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Prostate (2016) 0.75
Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens. Neoplasia (2017) 0.75
Clinical relevance of androgen receptor alterations in prostate cancer. Endocr Connect (2017) 0.75
Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells. Prostate (2017) 0.75
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell (2001) 5.88
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res (2012) 5.50
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol (2009) 3.86
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One (2011) 3.59
Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene (2000) 3.08
Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J Biol Chem (2004) 2.30
Alternative pathways of NF-kappaB activation: a double-edged sword in health and disease. Cytokine Growth Factor Rev (2006) 1.84
Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer (1991) 1.81
Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res (1995) 1.63
Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci U S A (2006) 1.46
Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res (2006) 1.30
Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res (2010) 1.29
Essential role of IkappaB kinase alpha in the constitutive processing of NF-kappaB2 p100. J Biol Chem (2005) 1.21
NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate (2008) 1.21
Regulation of NF-kappa B2 p100 processing by its cis-acting domain. J Biol Chem (2004) 1.17
Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells. Prostate (2010) 1.05
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol (2011) 3.57
An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A (2007) 3.54
Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene (2004) 2.82
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene (2003) 2.79
Topographic diversity of fungal and bacterial communities in human skin. Nature (2013) 2.79
Current applications for prostate-specific antigen doubling time. Eur Urol (2008) 2.76
Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer (2011) 2.36
Prevalence of unruptured cerebral aneurysms in Chinese adults aged 35 to 75 years: a cross-sectional study. Ann Intern Med (2013) 2.23
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet (2005) 2.08
CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol (2012) 2.05
Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol (2009) 1.90
Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res (2012) 1.81
Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res (2003) 1.80
Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol (2005) 1.69
Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004. J Urol (2009) 1.69
Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes Cancer (2010) 1.63
Stat3 activation in prostatic carcinomas. Prostate (2002) 1.61
Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clin Cancer Res (2006) 1.58
Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. Am J Pathol (2013) 1.53
MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem (2011) 1.52
Nonreceptor tyrosine kinases in prostate cancer. Neoplasia (2007) 1.50
Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene (2004) 1.48
Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci U S A (2006) 1.46
No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer (2013) 1.45
Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev (2007) 1.34
Acceptability of HIV/AIDS counseling and testing among premarital couples in China. AIDS Educ Prev (2005) 1.34
Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res (2004) 1.33
Minimising postoperative incontinence following radical prostatectomy: considerations and evidence. Eur Urol (2006) 1.33
Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res (2009) 1.32
Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol (2012) 1.32
MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One (2012) 1.30
Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res (2010) 1.29
Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol (2009) 1.26
Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Mol Cancer Ther (2005) 1.26
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs (2009) 1.26
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer (2007) 1.23
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res (2008) 1.21
NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate (2008) 1.21
Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. J Urol (2002) 1.20
Identification of Basonuclin2, a DNA-binding zinc-finger protein expressed in germ tissues and skin keratinocytes. Genomics (2004) 1.17
RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate (2004) 1.15
Urinary acylcarnitines are altered in human kidney cancer. Int J Cancer (2011) 1.14
Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate (2004) 1.14
Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res (2009) 1.13
Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate (2012) 1.10
Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol (2003) 1.10
Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res (2006) 1.09
Secondary malignancies among nonseminomatous germ cell tumor cancer survivors. Cancer (2011) 1.09
Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate (2006) 1.07
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac Oncol (2009) 1.06
Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells. Prostate (2010) 1.05
Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Hum Pathol (2008) 1.04
Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther (2013) 1.03
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther (2009) 1.02
Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol (2012) 1.02
Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. Genes Cancer (2010) 1.01
Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate (2008) 1.00
Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol (2011) 0.99
Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer. Cancer Genomics Proteomics (2005) 0.99
Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate (2005) 0.99
Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate (2013) 0.98
Testicular cancer metastatic exclusively to the brain and spleen. Urology (2004) 0.98